Apple's popular line of Beats wireless headphones is the subject of a filing for a potential class-action lawsuit alleging that the devices don't work as advertised for voice calls. The suit, filed in ...

“High Potential” continues to live up to its name. According to ABC, Season 2 of the hit drama continues to impress, currently serving as the fall’s No. 1 entertainment series in broadcast primetime ...

The Council for the Indian School Certificate Examinations (CISCE) is expected to announce the Class 10 (ICSE) and Class 12 (ISC) exam timetables for 2026 shortly. However, official confirmation is ...

SALT LAKE CITY — Names are already being gathered to possibly file a class action lawsuit after the events and cancellation at RedWest music festival this past weekend in Salt Lake City. "We ...

Potential for a Top 10 Day Wednesday for Omaha area ‘Second Amendment auditors’ walking Florida roads with AR-15 and body armor Trump Calls for NATO Action Against Russia Houthi rebels test US ...

As the sun sets over Philipsburg, the laughter of schoolchildren echoes down the narrow streets. Behind the scenes, teachers, parents, and policymakers are working together — not just to teach, but to ...

The Atlantic Coast Conference is known for being home to a handful of the NCAA's basketball powers. Schools like Duke, North Carolina and Louisville have made multiple Final 4 appearances and produced ...

SAN FRANCISCO--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an upcoming ...

The cast of ABC’s High Potential spends their days solving crimes on-screen, but at home, they’re busy raising kids. The crime drama — which returned for season 2 on Sept. 16 — and continues to follow ...

Christine is a freelance writer for Collider with two decades of experience covering all types of TV shows and movies spanning every genre. With a particular affinity for dramas, true crime, sitcoms, ...

Dosing of first patient in Phase 1 dose escalation trial of IDE892 targeted in 4Q 2025 Preclinical profile of IDE892 and mechanistic combination rationale with IDE397, IDEAYA's proprietary MAT2A ...